Device Trial Radar · NCT07335484
Aquarius Pilot Study to Evaluate the New Axonics Trial System
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Apr 30, 2026
Primary completion
Nov 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Axonics, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 13, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluation of the new Axonics External Trial System (ETS-02) in patients with overactive bladder (OAB) and/or fecal incontinence (FI).
Conditions
- Urinary Urge Incontinence (UUI)
- Urinary Frequency (UF)
- Fecal Incontinence (FI)
- Overactive Bladder (OAB)
Interventions
Axonics External Trial System (ETS)Device
A temporary electrode wire is passed through the S3 foramen with or without fluoroscopic guidance. The wire is then connected to an external pulse generator (EPG) and is worn for a trial period ranging from 3-7 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall FeasibilityTime frame: Day 5-7
- Adverse Events reporting (Safety)Time frame: Day 0-7
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
University of Birmingham, Alabama
Birmingham, Alabama · Recruiting
Atrium Health - Navicent
Macon, Georgia · Recruiting
University of Chicago
Chicago, Illinois · Recruiting
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.